- Latest available (Revised)
- Point in Time (02/07/2020)
- Original (As adopted by EU)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
Version Superseded: 11/08/2021
Point in time view as at 02/07/2020.
Commission Decision of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (notified under document number C(2002) 1344) (Text with EEA relevance) (2002/364/EC), Division 3. is up to date with all changes known to be in force on or before 20 October 2024. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations.
Changes and effects yet to be applied by the editorial team are only applicable when viewing the latest version or prospective version of legislation. They are therefore not accessible when viewing legislation as at a specific point in time. To view the ‘Changes to Legislation’ information for this provision return to the latest version view using the options provided in the ‘What Version’ box above.
Textual Amendments
F2 Substituted by Commission Implementing Decision (EU) 2019/1244 of 1 July 2019 amending Decision 2002/364/EC as regards requirements for HIV and HCV antigen and antibody combined tests and as regards requirements for nucleic acid amplification techniques with respect to reference materials and qualitative HIV assays (notified under document C(2019) 4632) (Text with EEA relevance).
by evaluation of the discrepant sample in further test systems,
by use of an alternative method or marker,
by a review of the clinical status and diagnosis of the patient, and
by the testing of follow-up-samples.
Diagnostic test sensitivity during sero-conversion has to represent the state of the art. Whether further testing of the same or additional sero-conversion panels is conducted by the notified body or by the manufacturer the results shall confirm the initial performance evaluation data (see Table 1). Sero-conversion panels should start with a negative bleed(s) and should have narrow bleeding intervals.
For blood screening devices (with the exception of HBsAg and anti-HBc tests), all true positive samples shall be identified as positive by the device to be CE marked (Table 1). For HBsAg and anti-HBc tests the new device shall have an overall performance at least equivalent to that of the established device (see 3.1.4).
Regarding HIV tests:
all sero-conversion HIV samples shall be identified as positive, and
at least 40 early sero-conversion HIV samples shall be tested. Results should conform to the state of the art.
specimens representing ‘ related ’ infections,
specimens from multipara, i.e. women who have had more than one pregnancy, or rheumatoid factor positive patients,
for recombinant antigens, human antibodies to components of the expression system, for example anti-E. coli, or anti-yeast.
The performance evaluation criteria for NAT assays can be found in Table 2.
Textual Amendments
F3 Inserted by Commission Implementing Decision (EU) 2019/1244 of 1 July 2019 amending Decision 2002/364/EC as regards requirements for HIV and HCV antigen and antibody combined tests and as regards requirements for nucleic acid amplification techniques with respect to reference materials and qualitative HIV assays (notified under document C(2019) 4632) (Text with EEA relevance).
Criteria for performance evaluation of reagents and reagent products for determining the blood groups antigens: ABO blood group system ABO1 (A), ABO2 (B), ABO3 (A,B); Rh blood group system RH1 (D), RH2 (C), RH3 (E), RH4 (c), RH5 (e); Kell blood group system KEL1 (K) can be found in Table 9.
by evaluation of the discrepant sample in further test systems,
by use of an alternative method,
CTS for Variant Creutzfeldt-Jakob disease (vCJD) assays for blood screening are set out in Table 11.]
Textual Amendments
Screening assays: anti-HIV 1/2, HIV 1/2 Ag/Ab, anti-HTLV I/II, anti-HCV, HCV Ag/Ab, HBsAg, anti-HBc
anti-HIV 1/2, HIV 1/2 Ag/Ab | Anti-HTLV-I/II | anti-HCV, HCV Ag/Ab | HBsAg | Anti-HBc | ||
---|---|---|---|---|---|---|
Diagnostic sensitivity | Positive specimens | 400 HIV-1 100 HIV-2 including 40 non-B-subtypes, all available HIV/1 subtypes shall be represented by at least 3 samples per subtype | 300 HTLV-I 100 HTLV-II | 400 (positive samples) Including samples from different stages of infection and reflecting different antibody patterns. Genotype 1-4: > 20 samples per genotype (including non-a subtypes of genotype 4); 5: > 5 samples; 6: if available | 400 including subtype-consideration | 400 including evaluation of other HBV-markers |
Sero-conversion panels | 20 panels 10 further panels (at Notified Body or manufacturer) | To be defined when available | 20 panels 10 further panels (at Notified Body or manufacturer) | 20 panels 10 further panels (at Notified Body or manufacturer) | To be defined when available | |
Analytical sensitivity | Standards | 0,130 IU/ml (WHO International Standard: Third International Standard for HBsAg, subtypes ayw1/adw2, HBV genotype B4, NIBSC code: 12/226) | ||||
Specificity | Unselected donors (including first-time donors) | 5 000 | 5 000 | 5 000 | 5 000 | 5 000 |
Hospitalized patients | 200 | 200 | 200 | 200 | 200 | |
Potentially cross-reacting blood-specimens (RF+, related viruses, pregnant women, etc.) | 100 | 100 | 100 | 100 | 100] |
NAT assays for HIV1, HCV, HBV, HTLV I/II (qualitative and quantitative; not molecular typing)
a European Pharmacopoeia guideline. | |||||||||
Notes: Acceptance criteria for ‘whole system failure rate leading to false-neg results’ is 99/100 assays positive. For quantitative NATs a study shall be performed on at least 100 positive specimens reflecting the routine conditions of users (e.g. no pre-selection of specimens). Comparative results with another NAT test system shall be generated in parallel. For qualitative NATs a study on diagnostic sensitivity shall be performed using at least 10 sero-conversion panels. Comparative results with another NAT test system shall be generated in parallel. | |||||||||
HIV1 | HCV | HBV | HTLV I/II | Acceptance criteria | |||||
---|---|---|---|---|---|---|---|---|---|
NAT | qualitative | quantitative | qualitative | quantitative | qualitative | quantitative | qualitative | quantitative | |
As for HIV quantitative | As for HIV quantitative | As for HIV quantitative | |||||||
Sensitivity Detection limit Detection of analytical sensitivity (IU/ml; defined on WHO standards or calibrated reference materials) | According to EP validation guideline a : several dilution series into borderline concentration; statistical analysis (e.g. Probit analysis) on the basis of at least 24 replicates; calculation of 95 % cut-off value | Detection limit: as for qualitative tests; Quantification limit: dilutions (half-log10 or less) of calibrated reference preparations, definition of lower, upper quantification limit, precision, accuracy, ‘ linear ’ measuring range, ‘ dynamic range ’ . Reproducibility at different concentration levels to be shown | According to EP validation guideline a : several dilution series into borderline concentration; statistical analysis (e.g. Probit analysis) on the basis of at least 24 replicates; calculation of 95 % cut-off value | According to EP validation guideline a : several dilution series into borderline concentration; statistical analysis (e.g. Probit analysis) on the basis of at least 24 replicates; calculation of 95 % cut-off value | According to EP validation guideline a : several dilution series into borderline concentration; statistical analysis (e.g. Probit analysis) on the basis of at least 24 replicates; calculation of 95 % cut-off value | ||||
Genotype/subtype detection/quantification efficiency | At least 10 samples per subtype (as far as available) | Dilution series of all relevant genotypes/subtypes, preferably of reference materials, as far as available | At least 10 samples per genotype (as far as available) | As far as calibrated genotype reference materials are available | As far as calibrated genotype reference materials are available | ||||
Cell culture supernatants (could substitute for rare HIV-1 subtypes) | Transcripts or plasmids quantified by appropriate methods may be used. | ||||||||
According to EP validation guideline a as far as calibrated subtype reference materials are available; in vitro transcripts could be an option | According to EP validation guideline a as far as calibrated subtype reference materials are available; in vitro transcripts could be an option | According to EP validation guideline a as far as calibrated subtype reference materials are available; in vitro transcripts could be an option | According to EP validation guideline a as far as calibrated subtype reference materials are available; in vitro transcripts could be an option | ||||||
Diagnostic specificity negative samples | 500 blood donors | 100 blood donors | 500 blood donors | 500 blood donors | 500 individual blood donations | ||||
Potential cross-reactive markers | By suitable assay design evidence (e.g. sequence comparison) and/or testing of at least 10 human retrovirus (e.g. HTLV)-positive samples | As for qualitative tests | By assays design and/or testing of at least 10 human flavivirus (e.g. HGV, YFV) positive samples | By assays design and/or testing of at least 10 other DNA-virus positive samples | By assay design and/or testing of at least 10 human retrovirus (e.g. HIV-) positive samples | ||||
Robustness | As for qualitative tests | ||||||||
Cross-contamination | At least 5 runs using alternating high positive (known to occur naturally) and negative samples | At least 5 runs using alternating high positive (known to occur naturally) and negative samples | At least 5 runs using alternating high positive (known to occur naturally) and negative samples | At least 5 runs using alternating high positive (known to occur naturally) and negative samples | |||||
Inhibition | Internal control preferably to go through the whole NAT procedure | Internal control preferably to go through the whole NAT procedure | Internal control preferably to go through the whole NAT procedure | Internal control preferably to go through the whole NAT procedure | |||||
Whole system failure rate leading to false-neg results | At least 100 samples virus-spiked with 3 × the 95 % pos cut-off concentration | At least 100 samples virus-spiked with 3 × the 95 % pos cut-off concentration | At least 100 samples virus-spiked with 3 × the 95 % pos cut-off concentration | At least 100 samples virus-spiked with 3 × the 95 % pos cut-off concentration | 99/100 assays positive |
Rapid tests: anti-HIV 1 and 2, anti-HCV, HBsAg, anti-HBc, anti-HTLV I and II
Anti-HIV 1/2 | Anti-HCV | HBsAg | Anti-HBc | Anti-HTLV I/II | Acceptance criteria | ||
---|---|---|---|---|---|---|---|
Diagnostic sensitivity | Positive specimens | Same criteria as for screening assays | Same criteria as for screening assays | Same criteria as for screening assays | Same criteria as for screening assays | Same criteria as for screening assays | Same criteria as for screening assays |
Sero-conversion panels | Same criteria as for screening assays | Same criteria as for screening assays | Same criteria as for screening assays | Same criteria as for screening assays | Same criteria as for screening assays | Same criteria as for screening assays | |
Diagnostic specificity | Negative specimens | 1 000 blood donations | 1 000 blood donations | 1 000 blood donations | 1 000 blood donations | 1 000 blood donations | ≥ 99 % (anti-HBc: ≥ 96 %) |
200 clinical specimens | 200 clinical specimens | 200 clinical specimens | 200 clinical specimens | 200 clinical specimens | |||
200 samples from pregnant women | 200 samples from pregnant women | 200 samples from pregnant women | 200 samples from pregnant women | ||||
100 potentially interfering samples | 100 potentially interfering samples | 100 potentially interfering samples | 100 potentially interfering samples | 100 potentially interfering samples |
Confirmatory/supplementary assays for anti-HIV 1 and 2, anti-HTLV I and II, anti-HCV, HBsAg
a Acceptance criteria no neutralisation for HBsAg confirmatory assay. | ||||||
Anti-HIV confirmatory assay | Anti-HTLV confirmatory assay | HCV supplementary assay | HBsAg confirmatory assay | Acceptance criteria | ||
---|---|---|---|---|---|---|
Diagnostic sensitivity | Positive specimens | 200 HIV-1 and 100 HIV-2 | 200 HTLV-I and 100 HTLV-II | 300 HCV (positive samples) | 300 HBsAg | Correct identification as positive (or indeterminate), not negative |
Including samples from different stages of infection and reflecting different antibody patterns | Including samples from different stages of infection and reflecting different antibody patterns. Genotypes 1 – 4: > 20 samples (including non-a subtypes of genotype 4); 5: > 5 samples; 6: if available | Including samples from different stages of infection 20 ‘ high pos ’ samples (> 26 IU/ml); 20 samples in the cut-off range | ||||
Sero-conversion panels | 15 sero-conversion panels/low titre panels | 15 sero-conversion panels/low titre panels | 15 sero-conversion panels/low titre panels | |||
Analytical sensitivity | Standards | Second International Standard for HBsAg, subtype adw2, genotype A, NIBSC code: 00/588 | ||||
Diagnostic specificity | Negative specimens | 200 blood donations | 200 blood donation | 200 blood donations | 10 false positives as available from the performance evaluation of the screening assay a . | No false-positive results/ a no neutralisation |
200 clinical samples including pregnant women | 200 clinical samples including pregnant women | 200 clinical samples including pregnant women | ||||
50 potentially interfering samples, including samples with indeterminate results in other confirmatory assays | 50 potentially interfering samples including samples with indeterminate results in other confirmatory assays | 50 potentially interfering samples including samples with indeterminate results in other supplementary assays | 50 potentially interfering samples |
HIV 1 antigen, HIV Ag/Ab, HCV antigen, HCV Ag/Ab
a The total number of seroconversion panels for combined Ag/Ab assays (from tables 1 and 5) need not be greater than 30.] | ||||
HIV-1 antigen and HIV Ag/Ab assays | HCV antigen and HCV Ag/Ab assays | Acceptance criteria | ||
---|---|---|---|---|
Diagnostic sensitivity | Positive specimens | 50 HIV-1 antigen positive 50 cell culture supernatants including different HIV-1 subtypes and HIV-2 | 25 HCV core antigen and/or HCV RNA positive but anti-HCV negative samples, comprising HCV genotypes 1-6 (if a genotype is not available, a justification shall be made) | See general principle in § 3.1.8 |
Sero-conversion panels a | 20 sero-conversion panels/low titre panels | 20 sero-conversion panels/low titre panels | ||
Analytical sensitivity | Standards | HIV-1 p24 Antigen, First International Reference Reagent, NIBSC code: 90/636 | HCV core antigen detection limit shall be investigated using dilutions of the WHO International HCV core antigen Standard: (HCV core Ag product code: PEI 129096/12) | For HIV-1 p24 antigen: ≤ 2 IU/ml |
Diagnostic specificity | 200 blood donations 200 clinical samples 50 potentially interfering samples | 200 blood donations, 200 clinical samples, 50 potentially interfering samples | ≥ 99,5 % after neutralisation or, if no neutralisation test available, after resolution of the sample status according to general principles in § 3.1.5 |
Serotyping and genotyping assay: HCV
HCV serotyping and genotyping assay | Acceptance criteria | ||
---|---|---|---|
Diagnostic sensitivity | Positive specimens | 200 (positive samples) Including samples from different stages of infection and reflecting different antibody patterns. Genotypes 1 – 4: > 20 samples (including non-a subtypes of genotype 4); 5: > 5 samples; 6: if available | ≥ 95 % agreement between serotyping and genotyping [X1> 95 % agreement between genotyping and sequencing] |
Diagnostic specificity | Negative specimens | 100 |
Editorial Information
HBV markers: anti-HBs, anti HBc IgM, anti-HBe, HBeAg
Anti-HBs | Anti-HBc IgM | Anti-HBe | HBeAg | Acceptance criteria | ||
---|---|---|---|---|---|---|
Diagnostic sensitivity | Positive specimens | 100 vaccinees | 200 | 200 | 200 | ≥ 98 % |
100 naturally infected persons | Including samples from different stages of infection (acute/chronic, etc.) The acceptance criteria should only be applied on samples from acute infection stage. | Including samples from different stages of infection (acute/chronic, etc.) | Including samples from different stages of infection (acute/chronic, etc.) | |||
Sero-conversion panels | 10 follow-ups or anti-HBs sero-conversions | When available | ||||
Analytical sensitivity | Standards | WHO First International Reference Preparation 1977; NIBSC, United Kingdom | HBe — Referenzantigen 82; PEI Germany | Anti-HBs: < 10 mIU/ml | ||
Diagnostic specificity | Negative specimens | 500 | 200 blood donations | 200 blood donation | 200 blood donations | ≥ 98 % |
Including clinical samples | 200 clinical samples | 200 clinical samples | 200 clinical samples | |||
50 potentially interfering samples | 50 potentially interfering samples | 50 potentially interfering samples | 50 potentially interfering samples |
HDV markers: anti-HDV, anti-HDV IgM, delta antigen
Anti-HDV | Anti-HDV IgM | Delta antigen | Acceptance criteria | ||
---|---|---|---|---|---|
Diagnostic sensitivity | Positive specimens | 100 | 50 | 10 | ≥ 98 % |
Specifying HBV markers | Specifying HBV markers | Specifying HBV markers | |||
Diagnostic specificity | Negative specimens | 200 | 200 | 200 | ≥ 98 % |
Including clinical samples | Including clinical samples | Including clinical samples | |||
50 potentially interfering samples | 50 potentially interfering samples | 50 potentially interfering samples |
Blood group antigens in the ABO, Rh and Kell blood group systems
1 | 2 | 3 | |
---|---|---|---|
Specificity | Number of tests per recommended method | Total number of samples to be tested for a launch product | Total number of samples to be tested for a new formulation, or use of well-characterised reagents |
Anti-ABO1 (anti-A), anti-ABO2 (anti-B), anti-ABO3 (anti-A,B) | 500 | 3 000 | 1 000 |
Anti-RH1 (anti-D) | 500 | 3 000 | 1 000 |
Anti-RH2 (anti-C), anti-RH4 (anti-c), anti-RH3 (anti-E) | 100 | 1 000 | 200 |
Anti-RH5 (anti-e) | 100 | 500 | 200 |
Anti-KEL1 (anti-K) | 100 | 500 | 200 |
All of the above reagents shall show comparable test results with established reagents with acceptable performance with regard to claimed reactivity of the device. For established reagents, where the application or use has been changed or extended, further testing should be carried out in accordance with the requirements outlined in column 1 (above).
Performance evaluation of anti-D reagents shall include tests against a range of weak RH1 (D) and partial RH1 (D) samples, depending on the intended use of the product.
:
10 % of the test population
:
> 2 % of the test population
:
> 40 % A, B positives
:
> 2 % of RH1 (D) positives
a Only by recommended techniques where reactivity against these antigens is claimed. | ||||||||
Note: Polyclonal reagents must be tested against a wider panel of cells to confirm specificity and exclude presence of unwanted contaminating antibodies. | ||||||||
Blood group reagents | Minimum number of control cells to be tested | |||||||
---|---|---|---|---|---|---|---|---|
Positive reactions | Negative reactions | |||||||
A1 | A2B | Ax | B | 0 | ||||
Anti-ABO1 (anti-A) | 2 | 2 | 2 a | 2 | 2 | |||
B | A1B | A1 | 0 | |||||
Anti-ABO2 (anti-B) | 2 | 2 | 2 | 2 | ||||
A1 | A2 | Ax | B | 0 | ||||
Anti-ABO3 (anti-A,B) | 2 | 2 | 2 | 2 | 4 | |||
R1r | R2r | WeakD | r’r | r’r | rr | |||
Anti-RH1 (anti-D) | 2 | 2 | 2 a | 1 | 1 | 1 | ||
R1R2 | R1r | r’r | R2R2 | r’r | rr | |||
Anti-RH2 (anti-C) | 2 | 1 | 1 | 1 | 1 | 1 | ||
R1R2 | R1r | r’r | R1R1 | |||||
Anti-RH4 (anti-c) | 1 | 2 | 1 | 3 | ||||
R1R2 | R2r | r’r | R1R1 | r’r | rr | |||
Anti-RH 3 (anti-E) | 2 | 1 | 1 | 1 | 1 | 1 | ||
R1R2 | R2r | r’r | R2R2 | |||||
Anti-RH5 (anti-e) | 2 | 1 | 1 | 3 | ||||
Kk | kk | |||||||
Anti-KEL1 (anti-K) | 4 | 3 |
Each batch of reagent must exhibit unequivocal positive or negative results by all recommended techniques in accordance with the results obtained from the performance evaluation data.
The phenotype of red cells used in the control of blood typing reagents listed above should be confirmed using established device.
Variant Creutzfeldt-Jakob disease (vCJD) assays for blood screening
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: